drugset / Trial / NCT05825391

Summary

The use of intracranial stents expands the possibilities for endovascular treatment of intracranial aneurysms and improves the success rate. However, it also increases the risk of ischemic complications in patients. The current standard dual antiplatelet regimen is considered crucial in reducing thrombotic events. Nevertheless, some patients exhibit resistance to antiplatelet drugs, which puts them at a higher risk of thrombotic events. In clinical practice, there is a lack of standardized platelet function testing and consensus on adjusting antiplatelet drug programs. This study conducted a multi-center, prospective cluster randomized controlled trial to investigate whether antiplatelet adjustment therapy guided by light transmittance aggregometry (LTA) detection can decrease the occurrence of ischemic events after stent implantation in patients with unruptured intracranial aneurysms. Additionally, the study aimed to establish a set of standardized antiplatelet regimens.

Timeline

Start
2023-05-04
Primary completion
2023-10-03
Completion
2023-10-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg Oral
Subject Aspirin Small molecule 200 mg Oral
Subject Clopidogrel Small molecule 37.5 mg Oral
Subject Clopidogrel Small molecule 75 mg Oral
Subject Ticagrelor Small molecule 45 mg
Subject Ticagrelor Small molecule 60 mg
Subject Ticagrelor Small molecule 90 mg

Indications